Literature DB >> 26058376

Re-evaluating the role of activin-βC in cancer biology.

Francesco Elia Marino1, Gail Risbridger2, Elspeth Gold3.   

Abstract

Transforming growth factor-β (TGF-β) superfamily signaling pathway and its ligands are essential regulators of cellular processes such as proliferation, differentiation, migration, and survival. Alteration of this pathway results in uncontrolled proliferation and cancer progression. This review focuses on a specific member of the TGF-β superfamily: activin-βC. After its initial discovery, activin-βC has been considered non-biologically relevant. Therefore, for years several experimental designs have ignored the potential contribution of this molecule to the final biological outcome. Here we focus on recent advances in the activin field, with a particular emphasis on activin-βC, its antagonistic mechanism, and the physiological relevance of activin-βC actions in reproductive and cancer biology. Covering a novel and previously unexplored function of activin-βC on cancer associated weight loss and muscle metabolism, this review suggests an imminent need to re-evaluate the function of activin-βC in biological systems and advances the understanding of how activin-βC antagonizes the activin signaling pathway. Thus, challenging activin biologists to consider the impact of activin-βC when interpreting their work.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activin-C; Cancer biology; Cancer cachexia; Gonadal tumor

Mesh:

Substances:

Year:  2015        PMID: 26058376     DOI: 10.1016/j.cytogfr.2015.05.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  1 in total

1.  Cytokine activin C ameliorates chronic neuropathic pain in peripheral nerve injury rodents by modulating the TRPV1 channel.

Authors:  Ya-Kun Huang; Yu-Gang Lu; Xin Zhao; Jing-Bing Zhang; Feng-Ming Zhang; Yong Chen; Ling-Bo Bi; Jia-Hui Gu; Zuo-Jie Jiang; Xiao-Man Wu; Qing-Yi Li; Yanli Liu; Jian-Xin Shen; Xing-Jun Liu
Journal:  Br J Pharmacol       Date:  2020-11-16       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.